Search

9/ 13/ 24, 4: 34 AM The New York Timeshttps:// nytimes. pressreader. com/ the- new- york- times/ 20240902 1/ 42 9/ 13/ 24, 4: 34 AM The New York Times https:// nytimes. pressreader. com/ the- new- york- times/ 20240902 14/ 42 [Extracted from the article]

The article investigates the growing industry of cutting babies' tongues in the U.S. and the abuse of the procedure for the purpose of increasing profits. It discusses the lactation problem experienced by mothers and presents caution from doctors about the complications of cutting babies' tongues. It reports the marketing and promotion of laser machines used for cutting babies' tongues to pediatric dentists and the rise of complaints to the International Board of Lactation Consultant Examiners.

The article reports on how device makers and doctors are allegedly reaping profits for promoting artery-opening procedures to patients with peripheral artery disease, with many patients losing their limb due to amputation in the process. It cites the case of Doctor Jihad Mustapha, who recommended the procedure to his patients to allegedly avoid amputations. Also cited is the claim by experts that even patients with severe artery disease should not take the procedure in short period of times.

The article reports on the operation of the nonprofit health organization Ascension, particularly the alleged shortage of staff in its hospitals in Chicago, Illinois and Flint, Michigan as a result of its move to terminate workers to bolster its profitability. Also cited are the complaints filed by its nurses due to inadequate staffing, and the alleged move by major nonprofit hospitals to avoid their charitable missions in exchange of profits.

The article reports on the National Association of Accountable Care Organizations study showing that there were over 450,000 Medicare beneficiaries whose accounts were billed for urinary catheters in 2023, an alleged sign of a billing scam. Also cited are the claim by account holder Linda Hennis that she never received any catheter despite her inclusion in the list, and the comment of the Medicare's Center for Program Integrity head Dara Corrigan on the issue.

The article exposes how the profits of Richmond Community Hospital in Virginia are seized by its owner, the nonprofit health care chain Bon Secours Mercy. It refers to a federal drug program as the hospital's source of profits. It reveals the stripping of hospital services after it was bought by Bon Secours in 1995 and how the chain took advantage of the 340B federal program to boost profits. It describes the struggle of doctors and nurses to provide proper medical care with limited supplies.

The article reports on a program called Rev-Up by non-profit hospital chain Providence, which aims to provide free health care to patients. Topics mentioned include instructions given to members of the hospital staff on how to approach patients and pressure them to pay, effort of Providence to avoid more than 1 billion U.S. dollars a year in taxes, and expenses of Providence on charity care in 2018.

The article focuses on Jihad Mustapha, known as the "leg saver," closing down his vascular clinics in Michigan after performing thousands of procedures that have been criticized for being unnecessary and potentially harmful.

The article reports that many surgeons have embraced the operation, known as a component separation, which is recommended only for large or complex hernias that are tough to close. Topics discussed include increase in the number of times doctors billed Medicare for a hernia component separation, danger brought by surgeons who taught themselves the operation by watching videos on social media, and remarks from Doctor Michael Rosen, a Cleveland Clinic surgeon.

The article reports on the alleged move by the U.S. Centers for Medicare and Medicaid Services (CMS) to exclude the violations of nursing homes in its ratings that allowed the homes to maintain their excellent grades. Among the alleged violations are sexual assault and bad practices. The ratings system is aimed at providing information to assess the quality and safety of nursing homes.

The article focuses on an investigation into a lactation consultant in Boise, Idaho, who may have been promoting an unproven procedure for breastfeeding issues. Topics covered include the surge in "tongue-tie" procedures, the lack of evidence supporting their effectiveness, and concerns raised by complaints about the consultant's practices.

The article reports on an investigation which revealed that 1 in 5 patients at nursing homes in the U.S. are falsely diagnosed with schizophrenia, and are given antipsychotic drugs, which double the chance of death for older people with dementia. Topics covered include Medicare data showing a 70 percent increase in the share of residents with a schizophrenia diagnosis from 2012 to 2021, and the fact that the government does not publicly divulge the use of antipsychotics at nursing homes.

The article reports on concerns over countries that have the potential to manufacture a vaccine for COVID-19. Topics include the number of countries that have restricted the export of protective equipment, medical devices or drugs, proposal of trade adviser Peter Navarro to force health care providers to buy protective gear and medicines from U.S. suppliers, and the number of potential vaccines that are in early stages of development around the world according to the World Health Organization.

The article explores how the pharmaceutical scandal involving Thalimodide, a sedative which caused birth defects in the 1950s and 1960s, has changed the way drugs are tested in the U.S. Topics covered include the number of babies in Germany, Great Britain, Australia and the U.S. that were born with severe defects after their mothers took the said drug, the revival of the Thalimodide tragedy due to the coronavirus pandemic and details of the lawsuits filed by U.S. survivors of thalidomide.

The article reports on the claim by nonprofit hospital chain Providence that it will refund payments made by over 700 low-income patients who were erroneously charged for medical care as a result of its program called Rev-Up, which is aimed at maximizing revenue. Also cited are the journal's move to investigate the Rev-Up program, and the lawsuit filed by Washington State Attorney General Bob Ferguson against Providence for alleged violations of state law.

The article informs that federal regulators would begin penalizing nursing homes that give residents a false label of schizophrenia, a practice that many facilities have used to skirt restrictions on antipsychotic drugs, which can be especially dangerous for older people.

The article reports on the home deliveries of millions of Covid rapid tests requested through the U.S. Postal Service website by the federal government in February 2022. It mentions the testing shortages faced by the government during the pandemic. A White House spokesman claimed that the contractors for the rapid test program including Abbott Laboratories and BinaxNOW will provide more than 550 million tests. Also noted is the initial commitment of Biden to make testing cheap and accessible.

The article reports on the move by U.S. pharmaceutical firm Merck as of February 2021 to focus on developing Covid-19 drugs and help competitors in supplying Covid-19 vaccines around the world. Also cited are the plan by the administration of President Joe Biden to enlist Merck in the manufacture of vaccines developed by Pfizer and Johnson & Johnson, as well as the comment of Merck chief marketing officer Michael T. Nally on their plans.

The article reports on the development of COVID-19 vaccines in the U.S. that offers new hopes to Americans amidst the surging cases of infections in the country as of February 2021. Among the vaccines with promising trial results are from Novavax and Johnson & Johnson. Also mentioned are the effectiveness of the AstraZeneca/University of Oxford vaccine against more contagious variants of the virus, and the move by President Joe Biden to increase his goal to vaccinate 150 million in 100 days.

The article reports on the claim by Novavax in January 2021 that its Covid-19 vaccine provided solid protection against the virus but it is less effective against the variant B.1.351 first discovered in South Africa. Topics include the claims by Pfizer and Moderna that their vaccines are also less effective against the new variant, and the comment by Novavax's Stanly Erck on the developments.

The article reports on the plan announced by U.S. President-elect Joseph R. Biden Jr. in January 2021 to significantly increase COVID-19 vaccination and the use of a wartime law to order an increase of vaccine production. Also cited are Biden's focus on racial equity in the vaccination program, his 1.9 trillion dollar rescue package to aid an economic recovery, and the comment of Doctor Michael T. Osterholm on the new threat of infections.

The article reports on the deal between the administration of U.S. President Donald Trump and pharmaceutical company Pfizer that would bolster supply of vaccine for Covid-19. Topics discussed include significance of the agreement, terms of the deal, and companies that worked more closely with the administration through its Operation Warp Speed to develop their vaccines.

The article reports on the approval by the U.S. Food and Drug Administration (FDA) in December 2020 of the emergency use authorization application of Pfizer for its COVID-19 vaccine. Topics include the complicated process of delivering the vaccines at ultracold temperatures to vaccinate health care workers and nursing home residents and the criticism hurled by President Donald Trump against the FDA.

The article reports on the recommendation by the U.S. Food and Drug Administration's (FDA) vaccine advisory panel as of December 2020 to the FDA to grant emergency authorization to Pfizer's Covid-19 vaccine for people 16 years old and above. The vaccination priorities are health care workers and nursing home residents. Also mentioned is the comment by Pfizer's Kathrin Jansen on the development.

The article reports on the alleged rejection by the administration of U.S. President Donald Trump in November 2020 to sign a contract for additional coronavirus vaccine doses on top of its 100 million order from pharmaceutical firm Pfizer. Also cited are Pfizer's successful vaccine trial, the projected shortage of vaccine supplies due to high cases of infections and hospitalizations in the country, and Trump's planned 'America First' executive order for vaccines.

The article reports on the possible development of coronavirus vaccines by several companies like Pfizer and Moderna, as well as the expected slow roll out of vaccination activities to Americans as of November 2020. Also cited are the challenges facing the companies in vaccine mass production like securing sufficient raw vaccine ingredients and producing consistent, high-quality batches, and the U.S. government's Operation Warp Speed to facilitate vaccine development.

The article reports on the claim by drug maker Pfizer in November 2020 that its coronavirus vaccine is more than 90% effective in preventing the virus based on its clinical trial. Topics include Pfizer's partnership with German firm BioNTech in developing the virus, the plan by Pfizer to apply for emergency authorization for its vaccine with the U.S. Food and Drug Administration (FDA).

The article reports on the claim by U.S. President Donald Trump in October 2020 that the antibody drug being developed by drug maker Regeneron is effective against Covid-19 based on his own experience and he would make it available for free for those who need it. Topics include the move by Regeneron to submit an application for emergency approval for the drug with the Food and Drug Administration and the funding it received from the federal government to mass manufacture the drug.

The article reports on the health condition of U.S. President Donald Trump as he was brought to the Walter Reed National Military Medical Center in Maryland due to a positive COVID-19 test result as of October 2020. Also cited are the claim by Trump's doctors that he was prescribed the steroid drug dexamethasone, as well as the comments by some medical experts like doctors Thomas McGinn and Esther Choo on Trump's situation.

The article reports on the claim by Pfizer chief executive officer Albert Bourla that they are eyeing to introduce a coronavirus vaccine in October 2020 amidst the pressure by U.S. President Donald Trump that a vaccine should be approved before the presidential election in November. Also cited are the threats to public safety if a vaccine is introduced without thorough testing, and the comment of Doctor Megan Ramney on the financial advantage to the firm that could develop a vaccine.

The article reports that drug companies Moderna and Pfizer have revealed plans on clinical trials for COVID-19 vaccine. Topics mentioned include concern among U.S. citizens about the drive of U.S. President Donald Trump to produce a vaccine before the November 2020 U.S. election, thoughts from Democratic presidential nominee Joseph R. Biden, Jr. on the process used to evaluate and approve a vaccine, and suspension of AstraZeneca's vaccine trial due to a serious illness in a participant.

The article discusses drug companies' lack of transparency on their vaccine clinical trials as of September 14, 2020. Topics covered include companies' standard of withholding trial details before completion, and their guarding of intellectual property and competitive edge. Also noted are the views of scientists and public health experts that American taxpayers should be apprised on vaccine status since the government has committed billions of dollars in vaccine research and purchase.

The article reports on the commitment made by a group of drug companies not to release any coronavirus vaccine that did not follow efficacy and safety standards amidst the political pressure from U.S. President Donald Trump for the issuance of a vaccine in October 2020. Among the companies are Moderna, Johnson & Johnson, and GlaxoSmithKline. Also cited are the plan by Food and Drug Administration (FDA) senior regulators to issue a similar statement.

The article reports that the surge in demand for plasma to treat Covid-19 patients has undercut research that could prove that it works. Topics covered include statement issued by U.S. President Donald Trump about the potential benefits of plasma, problems faced by researchers in recruiting sick people to participate in clinical trials, and a plan by the U.S. Food and Drug Administration to issue an emergency authorization to use the treatment.

The article discusses the pressure on U.S. scientists to quickly produce a coronavirus vaccine as of August 2020. Topics covered include President Donald Trump's need to check the pandemic before the November 2020 elections, researchers' struggles to ensure the balance between speed and regulation, and vaccines' enhanced safety and effectiveness if tested thoroughly before their release. Also noted are concerns on the administration's possible cutting of corners on vaccine development.

The article reports on the 1.6 billion U.S. dollar funding awarded to Novavax, a small biotechnology firm, by the administration of U.S. President Donald Trump to develop a vaccine against the coronavirus. Topics covered include the major technological advantage of Novavax despite never having brought a vaccine to market in its 33-year history, and the reason the Trump administration decided to invest in Novavax despite its poor track record and secrecy surrounding Operation Warp Speed.

The article profiles Stephanie Giordano, a researcher at drugmaker Regeneron who is working with a team to develop a vaccine for coronavirus disease-2019 (COVID-19). Topics covered include the vaccine, which is a cocktail of two antibodies, as one of the most promising treatments for COVID-19, Giordano's role in the vaccine development, and the long working hours that Giordano and her team went through in developing the vaccine that will enter clinical trials.

The article reports on the decision of the U.S. Biomedical Advanced Research and Development Authority (BARDA) to stop funding treatment research for COVID-19 in an aim to prioritize its focus on vaccine production. Topics discussed include comparison between the BARDA funding for treatments against vaccine production, impact on the works of academic researchers and small biotechnology firms, and the adverse effects on the health care system.

The article reports on a dispute over who should pay for worker COVID-19 testing, as part of a national effort in the U.S. to reduce the virus' spread in nursing homes. Topics discussed include estimated number of residents in nursing homes who have died of the virus, according to a report released on June 4, 2020 by the U.S. Centers for Medicare and Medicaid Services, and significance of regular testing of nursing home staff.

The article reports on why the level of testing for coronavirus in the U.S. was less than what many epidemiologists say it would be in terms of magnitude. Topics covered include the lack of coordination among public and private health labs, and the fragmented, poorly organized American health care system, which made it difficult for hospitals and other medical providers to quickly overcome hurdles to testing.

The article reports on the decision of U.S. President Donald Trump to continually take an antimalarial drug, hydroxychloroquine, as a preventive measure from the Wuhan coronavirus despite a warning from the Food and Drug Administration (FDA). Topics discussed include possible impact of hydroxychloroquine on COVID-19 patients according to FDA, remarks from Trump on the positive effect of the drug, and the public's reaction to Trump's use of hydroxychloroquine due to the risks it poses.

The article reports on the lack of dialysis during the COVID-19 pandemic for COVID-19 patients fighting kidney failure. Topics mentioned include an increase in demand for dialysis at hospitals in New York City at the peak of the pandemic, percentage of intensive care unit patients with COVID-19 around the U.S. who suffered kidney failure and needed emergency dialysis, and the case of 68-year-old COVID-19 patient Jamal Uddin in Brooklyn.

The article reports on the plan of U.S. Senate Democrats to build a fast and free testing to track the path and penetration of the 2019 novel coronavirus. Topics mentioned include a conference call of U.S. President Donald Trump on restarting the economy, the request of New York Governor Andrew M. Cuomo for federal assistance to ramp up testing, and the failure of the U.S. Food and Drug Administration to speed approval for commercial laboratories to make tests widely available.

The article reports on the response of health officials in the U.S. to the short supply of test kits in the country for the 2019 novel coronavirus. Topics mentioned include the number of tests conducted in California as of March 5, 2020, a promise made by U.S. President Donald Trump about 1 million to 1.5 million tests to be sent around the country, and an emergency spending bill for the coronavirus worth 8.3 billion U.S. dollars.

The article reports on coronavirus diagnostic criteria of the U.S. Centers for Disease Control and Prevention (CDC). Topics discussed include remarks from Julie Vaishampayan, public health officer of Stanislaus County in Modesto, California, promise of the administration of President Donald Trump to expand the nation's testing capabilities, and amount the House and Senate agreed to provide to combat the spread of the coronavirus.

The article reports that labor unions have expressed their support for U.S. House Speaker Nancy Pelosi's bill to lower drug prices. The United Auto Workers and the American Federation of Labor and Congress of Industrial Organizations (AFL-CIO) have supported the bill. In response, the Pharmaceutical Industry Labor-Management Association has launched advertisements on Facebook to defeat the proposal.

The article discusses an investigation that found that Medicare's rating system for nursing homes in the U.S. used incomplete information that could mislead consumers and investors about nursing home conditions. Topics addressed include lawsuits filed against nursing home company North American Health Care's Rosewood Post-Acute Rehab nursing home, which received a five-star rating from Medicare, as well as concerns regarding the impact of inflated ratings on the public's assessment of nursing homes.

The article reports on the growth of the electronic cigarette and vaping industry in the U.S. since 2009. Topics discussed include setbacks suffered by the Food and Drug Administration in trying to regulate the products as drugs, plans of the government to impose a flavor ban for e-cigarettes, description of the earliest forms of e-cigarettes, and e-cigarette bans in several states in response to vaping illnesses and deaths.